COVID-19
TOOLBOX
Filter
533
Featured
Language
Document type
278
86
49
41
21
14
13
12
9
5
2
2
1
Countries / Regions
49
43
29
27
22
21
20
20
16
15
13
11
10
10
10
9
7
5
5
4
4
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
174
24
24
23
18
14
14
13
12
11
10
8
7
7
6
6
6
6
6
5
5
5
5
5
5
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
Category
221
30
20
16
9
4
2
VOX Sanguinis, 2021: The coronavirus disease 2019 (COVID-19) affected millions of people worldwide and caused disruptions at the global level including in healthcare provision. Countries of the WHO African region have put in place measures for the COVID-19 pandemic containment that may adversely a ... more
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States. Currently ... more
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ... more
19 February 2021 The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the class effect of anti-IL-6 therapies. It will also es ... more
wird ständig aktualisiert

In the wake of the pandemic. Preparing for Long COVID-19

Rajan, S.; et al. World Health Organization WHO, Regional Office of Europe (2021) C_WHO
Policy Brief. Our understanding of how to diagnose and manage Long COVID is still evolving but the condition can be very debilitating. It is associated with a range of overlapping symptoms including generalized chest and muscle pain, fatigue, shortness of breath, and cognitive dysfunction, and the ... more
The latest update (28 January 2021) includes the following addition and revision: biosafety aspects for working with antigen-detecting rapid diagnostic test; handling new variants of SARS-CoV-2 in the laboratory; updated assay decontamination before disposal; personal protectiv ... more
The latest update (28 January 2021) includes the following addition and revision: biosafety aspects for working with antigen-detecting rapid diagnostic test; handling new variants of SARS-CoV-2 in the laboratory; updated assay decontamination before disposal; personal protectiv ... more
Interim guidance 2 march 2021 Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform ... more
04.März 2021 MEDBOX Issue Brief no. 10 Dieser Issue Brief gibt einen kurzen Überblick über Teststrategie, Testverfahren, Videos zur Handhabung und weiterführende Literatur.
Actualizadas en el documento titulado «Vigilancia de salud pública en relación con la COVID-19» publicado el 16 de diciembre de 2020
Обновление рекомендаций по санитарно-эпидемиологическому надзору за COVID-19 от 16 декабря 2020 г
Actualisées dans « La surveillance de la santé publique dans le contexte de la COVID-19 », publié le 16 décembre 2020
Основные аспекты обеспечения биологической безопасности в лабораторных условиях в связи с распространением вируса SARS-CoV
28 January 2021. The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients.
28 Jan. 2021. L’objet de ce document est de fournir des orientations provisoires sur la sécurité biologique en laboratoire applicable à l’analyse d’échantillons cliniques issus de patients.
23 February 2021 This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc ... more
23 February 2021 This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc ... more